The purpose of this study was to investigate histamine and skin mast cells in psoriasis before and during 6 months of treatment with high-dose ranitidine. Sixteen psoriasis patients, presenting a mean PASI score of 15.4, were compared with 13 age-and sex-matched healthy controls. Resting extracellular skin levels of histamine and histamine release to mast cell secretagogues, as measured by the microdialysis technique, were increased in involved psoriasis skin compared to normal skin in the controls. Plasma histamine, but not basophil histamine release, was signi¢cantly increased in the patients. Mast cells and lymphocytes were signi¢cantly increased in numbers in involved versus non-involved skin in the patients, the lymphocytes being predominantly T-lymphocytes expressing HLA-DR activation. During 6 months of ranitidine treatment, mean PASI score of 15.4 decreased to 5.8. The lymphocyte in¢ltration, but not mast cell numbers, was signi¢cantly reduced during treatment, and histamine release to mast cell secretagogues was normalized. These observations suggest that skin mast cells in active psoriasis are functionally hyperreactive. The biochemical ¢ndings together with the clinical e¡ect of ranitidine indicate that histamine may be involved in the pathophysiology of psoriasis. Studies have indicated that psoriasis is a T-cell dependent autoimmune disease which develops primarily in genetic susceptible subjects. A variety of e¡ector cells and in£ammatory and proin£ammatory mediators may be involved in the pathophysiology (1, 2).
Studies have indicated that psoriasis is a T-cell dependent autoimmune disease which develops primarily in genetic susceptible subjects. A variety of e¡ector cells and in£ammatory and proin£ammatory mediators may be involved in the pathophysiology (1, 2) .
Based on circumstantial evidence, mast cells and histamine may be involved in the pathophysiology of psoriasis. First, dermal in¢ltration of mast cells is one of the earliest ¢ndings in developing psoriasis lesions, and mast cells are consistently demonstrated in increased numbers in active psoriasis plaques (3, 4) . Second, sensory nerve cell^mast cell interactions are altered in psoriasis. The number of neuropeptide containing sensory nerves is increasingly expressed in psoriatic skin, and the numbers of contact sites between nerve ¢bres and mast cells are increased (5) . Neuropeptides may interact with mast cells bi-directionally. Upon intradermal injection in human skin, neuropeptides, including substance P and vasoactive intestinal peptide, cause vasodilation and plasma extravasation, entirely or partially, by their ability to release histamine from human skin mast cells as shown in vitro and in vivo (6) . In addition to being activated by neuropeptides, mast cells may regulate neuropeptide activity. Mast cell proteases, such as tryptase and chymase, may play a crucial role in neurogenic in£ammation in psoriasis because of their neuropeptide-degrading activities, which seemed to be impaired in psoriasis (7) . Third, the involvement of histamine in the pathogenesis of psoriasis is substantiated by clinical improvement during long-term treatment with H 2 -receptor antagonists (8, 9) . The possible roles of histamine in psoriasis have been discussed recently (10) .
The purpose of this study was to investigate histamine, mast cells and basophils in psoriasis and to follow these parameters during therapy with high-dose ranitidine.
MATERIALS AND METHODS

Subjects
Sixteen patients su¡ering from psoriasis vulgaris participated in the study. Median PASI score at entry was 15.4 (range 9.0^24.7). The patients are described in detail elsewhere (9) . The control group consisted of 13 healthy, non-medicated age-and sex-matched subjects. All participants gave informed consent, and the study was approved by the ethics committee of Copenhagen hospitals and the Danish National Board of Health.
Microdialysis and instrumentation
A microdialysis technique was used to measure histamine levels in intact skin. Single dialysis ¢bres of 216 m diameter, 2 kDa molecular weight cut o¡, and 20 mm length for di¡usion were inserted in EMLAtreated skin (11, 12) . Three dialysis ¢bres were inserted at a distance of at least 3 cm between adjacent ¢bres. In most patients, dialysis ¢bres were inserted in separate psoriasis plaques in the same anatomical region. A reconstitution phase of 2 h was interposed before any measurements (12) . Local anaesthetics do not e¡ect histamine release (13) .
For determination of histamine levels in unchallenged skin sites, each ¢bre was perfused with Krebs Ringer bicarbonate at a rate of 1.0 l/min for 60 min. Control experiments were performed to compare di¡usion characteristics of extracellular compounds in psoriatic and normal skin. The dialysate/plasma glucose concentration ratio was selected as an indicator for di¡usion characteristics since glucose rapidly equilibrates within the extracellular water space and skin concentrations are identical with plasma concentrations during steady state (11) .
After measurement of histamine levels in unchallenged skin, histamine release by codeine and substance P was studied. The perfusion rate was 3.0 l/min and sampling fractions were 6 ml, which allowed a detailed characterization of histamine release (12) . Fifty ml aliquots of codeine (250 mM), substance P (2 mM), or vehicle (saline with 0.02% human serum albumin) were injected intradermally above individual ¢bres. Dialysates were collected in 6 ml fractions before (^4 to 0 min) and from 0 to 14 min after the injection at 2-min intervals.
Histological examinations and immunohistochemistry
Histological examinations were performed in the patients, not in the corresponding controls. Four 3-mm punch biopsies were taken from involved and non-involved skin before and after 3 and 6 months of treatment. The biopsy locations were symmetrically chosen and, for each individual patient, they were performed in the same anatomical region every time.
One set of biopsies was prepared for immunohistochemical analysis. The other set was formalin-¢xed and stained with haematoxylin-eosin, chloroacetate esterase, or the antibodies UCHL-1 (anti-CD45R0, 1:200), L-26 (anti-CD20, 1:100) and anti-HLA-DR 1:25 (DAKO, Glostrup, Denmark). Chloroacetate esterase stained mast cells as well as granulocytes, but granulocytes were infrequently found in psoriatic skin and they could be easily recognized by their lobulated nuclei. Cryostat skin sections were stained with anti-CD4 and anti-CD8 antibodies (DAKO).
An Olympus BHS microscope and a computerized optical dissector video system (GRID 1 Medicosoft, Silkeborg, Denmark) was used. In each biopsy, 30 test grids (0.17 mm 2 ) were counted. Frames were counted from the basement membrane, 3 rows of 10 adjacent frames perpendicular to the epidermis were visualized. The count were expressed as cells/mm 2 . A 4-point semiquantitative score from zero to 3z was used to describe HLA-DR staining, representing no staining, weak staining, moderate staining and strong staining. The CD4 / CD8 ratio was expressed as 1:1, 2:1 or 3:1 respectively.
Basophil histamine release
Histamine release from washed whole blood was performed as previously described (14) . In short, blood was drawn into heparinized glass, mixed with Pipes bu¡er, gently centrifuged, the supernatant was discharged, and the blood cells were resuspended in Pipes bu¡er. The blood cells were challenged with anti-IgE (0.4^400 U/ml) and bu¡er. Basophil sensitivity (the concentration of anti-IgE causing the release of w20% of total basophil histamine content), maximum histamine release to anti-IgE, and total basophil histamine content were analysed.
Mediator assays
Histamine concentrations, except for those in plasma, were analysed using a glass ¢bre-based spectro£uorometric assay (15) . The detection limit of this assay is 25 nM histamine (12) . Plasma concentrations of histamine and stem cell factor were analysed using commercially available enzyme immunoassays without modi¢cations (histamine: Immunotech, Marseille, France, sensitivity 0.2 nM; stem cell factor: Amersham, Buckinghamshire, U.K., sensitivity 3 pg/ml). Glucose concentrations were analysed on a Beckman II Analyzer (Beckman Instruments, Fullerton, CA).
Treatment
The patients, not the controls, were treated with the H 2 -receptor antagonist ranitidine (Zantac 1 , Glaxo) 300 mg orally twice daily for 6 months as previouly described (9) . Systemic drugs and ultraviolet irradiation were stopped 4 weeks before entry, so were local drugs 2 weeks before entry.
Statistics
Descriptive statistics included calculation of mean¡SEM if not otherwise stated. The non-parametric Friedman and Kruskal-Wallis analysis of variance tests were used for paired and unpaired measurements of more than two sets of data, whereas the Wilcoxon and MannWhitney tests were used in the case of paired or unpaired two-sample data. P-values less than 0.05 were considered statistically signi¢cant.
RESULTS
Clinical outcome
Mean PASI score declined from 15.4 to 12.7, 9.1 and 5.8 after 1, 3 and 6 months of treatment, respectively (pv0.001). Further details of the clinical results of these patients (patients 1^16) plus four additional patients have been presented in detail elsewhere (9).
Histamine measurements
In this section, data from involved skin in the patients were compared with data from normal skin of healthy volunteers. Histamine levels in unchallenged skin in the patients before treatment were 50.3¡8.1 nM compared with 31.3¡2.7 nM in the controls (pv0.05). The dialysis e¤cacy, estimated as the dialysate/plasma glucose ratio, was identical in the patients and in the controls, the ratios being 0.45¡0.03 and 0.44¡0.02, respectively. Plasma histamine concentrations of 3.71¡0.33 nM in the patients were signi¢cantly increased compared to control values of 2.55¡0.31 nM (pv0.01). In patients and controls, skin histamine levels were 12^14 fold the values in venous plasma (pv0.001). During treatment skin histamine concentrations rose from 50.3¡8.1 nM to 76.7¡10.8, 74.5¡7.6, and 68.1¡11.9 nM after 1, 3 and 6 months of treatment [not statistically signi¢cant (NS)]. Plasma histamine decreased from 3.71¡0.33 nM to 2.99¡0.26, 2.70¡0.20, and 2.76¡0.36 nM at 1, 3 and 6 months (NS). Skin/plasma glucose ratio was constant throughout the 6-month study period (data not shown).
Total histamine content was 188.9¡34.2 and 132.5¡22.1 ng histamine in 100 mg wet weight skin in the patients before and after 6 months of treatment (NS).
There were no statistically signi¢cant di¡erences between patient and controls regarding basophil sensitivity or maximum histamine release to anti-IgE, or total basophil histamine content (data not shown). Further, plasma concentrations of stem cell factor in the patients (1183¡51 ng/ml) were similar to control values (1162¡45 ng/ml).
Substance P and codeine released signi¢cant amounts of histamine in the patients as well as in the controls compared to bu¡er sites (pv0.001) (Fig. 1) . Peak histamine release by substance P of 270.8¡60.5 nM in the patients before treatment were almost twice that seen in the controls (150.2¡34.6 nM), but this di¡erence did not reach statistical signi¢cance. Total histamine release was 4.06¡1.04 and 2.81¡0.67 pmol in 14 min (NS). Codeine-induced peak histamine release of 725.9¡195.1 nM in untreated patients was signi¢cantly larger than control values of 99.5¡22.7 nM (pv0.01). Total histamine releases were 9.77¡2.33 and 1.67¡0.40 pmol (pv0.01). In most cases, peak histamine concentrations were found 4 min after skin challenge in patients and controls. After 6 months of treatment, substance P-induced and codeineinduced peak histamine release was reduced from 270.8¡60.5 to 104.2¡11.9 nM (pv0.05) and 725.9¡195.1 to 122.1¡25.9 nM (pv0.01).
Histological examinations
In this section, data from involved and non-involved skin in the patients were compared. Fig. 2 shows mast cell and lymphocyte numbers before and during treatment. Before treatment, the numbers of mast cells in involved and non-involved skin were 127¡15 and 91¡13 cells/mm 2 (pv0.05). There were no signi¢cant changes in mast cell numbers in either involved or non-involved skin during treatment. There was a pronounced in¢ltration of lymphocytes in involved skin (446¡84 cells/ mm
2 ) compared to non-involved skin (131¡12 cells/mm 2 ) before treatment (pv0.001). During treatment the numbers of lymphocytes decreased in both involved (pv0.001) and non-involved skin (pv0.01).
Immunohistochemical staining in involved skin showed that the lymphocytes represented predominantly T-lymphocytes. The CD4z/CD8z ratio was 23% (1 : 1), 46% (2 : 1), and 31% (3 : 1); this did not change signi¢cantly during treatment. Values in non-involved skin were not analysed. HLA-DR immunostaining was signi¢cantly increased in involved skin (0: 7%, z: 36%, zz: 36%, and zzz: 21%) compared to non-involved skin (0: 15%, z: 85%) (pv0.05). No signi¢cant changes were observed during treatment.
DISCUSSION
Several ¢ndings in this study suggested alterations in mast cell characteristics and functions in psoriatic skin. Compared to control skin in healthy volunteers, mast cells were higher in numbers, skin and plasma histamine concentrations were increased, and histamine release to mast cells secretagogues were raised.
Dialysate histamine levels in psoriatic skin were higher than in the skin of healthy controls. Since the di¡usion capacity was similar in patients and controls, this observation seems to re£ect increased extracellular histamine levels in psoriatic skin. Skin histamine levels of histamine were higher than plasma levels in patients and controls, suggesting a low incessant histamine release from skin mast cells in both groups. Since mast cell numbers and total skin histamine content in the healthy controls, as well as histamine metabolism in general, were not measured, we can only speculate whether the increased plasma histamine levels re£ected increased incessant skin mast cell degranulation in the patients. During treatment with ranitidine, skin histamine concentrations remained unchanged or increased slightly, and histamine release to substance P and codeine was normalized. Mast cell numbers did not change signi¢cantly, nor did total skin histamine content. The ¢nding of a constant increased number of mast cells during successful antipsoriatic treatment is in accordance with previous ¢ndings (16, 17) . The ¢ndings of unaltered mast cell numbers and total skin histamine content along with decreased histamine release to mast cell secretagogues during treatment suggest a decrease in histamine releasibility during remission.
Previously, increased histamine releasibility has been demonstrated in bronchoalveolar mast cells in atopic asthma patients, and in basophil and eosinophil granulocytes in atopics (18, 19) . Increased mast cell releasibility has been shown in the skin of chronic urticaria patients and this increased releasibility normalized during spontaneous remissions (20, 21) . A consistent histological ¢nding in chronic urticaria skin sites as well as in psoriasis plaques is a cellular in¢ltrate dominated by T-lymphocytes. This has led some authors to hypothesize that increased mast cell releasibility in urticaria is closely related to lymphocyte-derived histamine-releasing factors which locally modify the degranulation processes. In this study the number of T-lymphocytes decreased signi¢cantly along with decreased histamine releasibility, but the data do not provide a causative explanation for these alterations. The histamine-releasing factors remain to be determined. However, neither peripheral blood mononuclear cell-derived histaminereleasing factors nor the most potent of these factors, the CCchemokines in human cloned forms, release histamine from human skin mast cells (22, 23) . Stem cell factor, which is a potent histamine-releasing cytokine of skin mast cells (22) , was not found in increased concentrations in the systemic circulation in the patients compared to healthy controls. Skin stem cell factor concentrations could not be assessed because of methodological aspects. Increased skin mast cell releasibility seemed not to be related to atopic skin diseases exclusively, but may be triggered by local factors. The possible e¡ects of extracellular matrix and cellular components on mast cells functions in vivo warrant further studies.
The mast cell secretagogues codeine and substance P induced histamine release in the patients compared to the controls 10-fold and 2-fold, respectively. Immunohistochemical reports have suggested impaired degradation of substance P in the skin of psoriatics (7) . Histamine release to substance P in patients and controls was not signi¢cantly di¡erent, which suggests a normal neuropeptide-induced mast cell activation in psoriasis. The exact mechanism by which these compounds degranulate mast cells remains unsolved, but it appears to occur via the same, non-receptor mediated, G-protein activation (6) . Our data allow no valid explanation for the di¡erence in magnitude of histamine release in the patients compared to the controls for these two substances.
We are aware of the fact that the design of this study makes it di¤cult to interpret changes in clinical and biochemical data during treatment. It remains to be elucidated whether the observed biochemical changes occurred exclusively as a consequence of treatment e¡ect. It is generally believed, however, that H 2 -receptor antagonists do not modulate histamine release from human skin mast cells (24) . Also, non-involved skin in psoriasis may show signs of altered biochemical functions and cellular composition. The design of the present study did not allow detailed studies of such alterations. Additional studies may further reveal the pathophysiological roles of histamine in evolving psoriasis, and explore the therapeutical use of H 2 -antihistamines in controlled clinical trials.
